Amicus Therapeutics, Inc.
FOLD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,431 | $1,765 | $2,511 | $2,867 |
| - Cash | $191 | $159 | $182 | $214 |
| + Debt | $443 | $443 | $443 | $444 |
| Enterprise Value | $2,683 | $2,049 | $2,773 | $3,097 |
| Revenue | $169 | $155 | $125 | $150 |
| % Growth | 9.3% | 23.5% | -16.3% | – |
| Gross Profit | $148 | $139 | $114 | $135 |
| % Margin | 87.4% | 90.2% | 90.7% | 90.1% |
| EBITDA | $48 | -$6 | -$5 | $22 |
| % Margin | 28.3% | -3.7% | -3.8% | 14.7% |
| Net Income | $17 | -$24 | -$22 | $15 |
| % Margin | 10.2% | -15.8% | -17.3% | 9.8% |
| EPS Diluted | 0.056 | -0.08 | -0.07 | 0.049 |
| % Growth | 169.8% | -14.3% | -242% | – |
| Operating Cash Flow | $36 | -$27 | $8 | -$4 |
| Capital Expenditures | -$0 | -$2 | -$0 | -$0 |
| Free Cash Flow | $35 | -$29 | $8 | -$4 |